We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Communications that Amylin Pharmaceuticals made about its diabetes drug candidate Symlin will fall under the scrutiny of the Securities and Exchange Commission (SEC) under an informal inquiry, the company announced last month.